Affiliation:
1. DataHow AG Zurich Switzerland
2. Biologics Development Global Product Development and Supply Bristol Myers Squibb Devens Massachusetts USA
Abstract
AbstractThe use of hybrid models is extensively described in the literature to predict the process evolution in cell cultures. These models combine mechanistic and machine learning methods, allowing the prediction of complex process behavior, in the presence of many process variables, without the need to collect a large amount of data. Hybrid models cannot be directly used to predict final product critical quality attributes, or CQAs, because they are usually measured only at the end of the process, and more mechanistic knowledge is needed for many classes of CQAs. The historical models can instead predict the CQAs better; however, they cannot directly relate manipulated process parameters to final CQAs, as they require knowledge of the process evolution. In this work, we propose an innovative modeling approach based on combining a hybrid propagation model with a historical data‐driven model, that is, the combined hybrid model, for simultaneous prediction of full process dynamics and CQAs. The performance of the combined hybrid model was evaluated on an industrial dataset and compared to classical black‐box models, which directly relate manipulated process parameters to CQAs. The proposed combined hybrid model outperforms the black‐box model by 33% on average in predicting the CQAs while requiring only around half of the data for model training to match performance. Thus, in terms of model accuracy and experimental costs, the combined hybrid model in this study provides a promising platform for process optimization applications.
Reference27 articles.
1. U.S. Food and Drug Administration. (2004).Pharmaceutical CGMPs for the 21st Century – A Risk Based Approach; Final Report. U.S. Food and Drug Administration: Silver Spring.
2. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives
3. ICH Q8 (R2). (2009).Pharmaceutical development ICH Harmonized Tripartite Guidelines.International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
4. Multivariate PAT solutions for biopharmaceutical cultivation: current progress and limitations
5. Assessment of Recent Process Analytical Technology (PAT) Trends: A Multiauthor Review
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献